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69 Objective: The octanoylated peptide hormone ghrelin regulates appetite and glycaemic control. 
70 Des-acyl ghrelin abolishes some effects of ghrelin, but does not bind to ghrelin receptor. LEAP2 is a 
71 novel ligand for ghrelin receptor that blocks the effects of ghrelin. Some evidences show that 
72 plasma levels of these peptides are altered adults with obesity, but their levels in childhood 
73 obesity remain poorly studied. Therefore, the objective of this study was to assess fasting plasma 
74 levels of ghrelin, des-acyl ghrelin and LEAP2 in children with normoweight, overweight/obesity 
75 and their association with different anthropometric and metabolic variables. Design: A total of 42 
76 females and 40 males, ages 3-12 years-old were enrolled as a cross-sectional cohort. Results: 
77 Plasma levels of des-acyl ghrelin and LEAP2 (but not ghrelin) were lower and ghrelin/des-acyl 
78 ghrelin ratio was higher in children with overweight/obesity. Des-acyl ghrelin negatively correlated 
79 with age, BMI z-score, insulin and HOMA index, and the correlations were stronger in children with 
80 overweight/obesity. LEAP2 levels negatively correlated with BMI z-score. No gender differences 
81 were found. Conclusions: Our findings suggest that ghrelin tone is increased in childhood obesity, 
82 due to a decrease on plasma levels of des-acyl ghrelin and LEAP2, and that des-acyl ghrelin is 
83 associated to insulin resistance, particularly in children with overweight/obesity.
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86 Ghrelin is a gastrointestinal tract-derived hormone that acts via the growth hormone 
87 secretagogue receptor (GHSR) (1). Ghrelin is a 28-residues peptide that contains an n-octanoyl 
88 ester at its third serine residue, an unusual posttranslational modification catalyzed by the enzyme 
89 ghrelin O-acyltransferase (2). This lipid modification is essential for the bioactivity of ghrelin (1). 
90 Administration of ghrelin to healthy individuals increases hunger/food intake and promotes 
91 mechanisms that increase glycaemia (3). Administration of ghrelin decreases insulin secretion (4) 
92 and increases plasma levels of growth hormone (GH), adrenocorticotropic hormone and cortisol 
93 (3). In plasma, ghrelin also exists as a des-octanoylated form, hereafter named des-acyl ghrelin 
94 (DAG). DAG is either secreted from ghrelin-producing cells of the gastrointestinal tract, or results 
95 from ghrelin des-acylation in plasma (2). The role of DAG is uncertain since DAG does not bind to 
96 GHSR at physiological ranges, and no DAG receptor has been identified, yet. Strikingly, DAG 
97 modulates genes involved in glucose and lipid metabolism in mice lacking GHSR, suggesting a 
98 GHSR-independent action (5). In humans, plasma DAG levels are higher than ghrelin levels, and 
99 some studies show that DAG infusion improves glucose metabolism (6, 7) and that concomitant 
100 administration of DAG and ghrelin abolishes the hyperglycaemic effects of ghrelin (8). However, 
101 other studies could not confirm such observations (9). Recently, liver antimicrobial peptide 2 
102 (LEAP2) has been identified as another ligand of GHSR (10). LEAP2 is a 40-residues peptide 
103 primarily secreted by the liver and jejunum (10). LEAP2 blocks ghrelin-induced activation of GHSR 
104 and also reduces GHSR constitutive activity (11, 12). In mice, LEAP2 blocks the stimulatory effects 
105 of ghrelin on food intake and GH secretion, and plasma LEAP2 levels display an inverse 
106 relationship to plasma ghrelin levels: LEAP2 levels decrease under fasting and increase to basal 
107 levels upon refeeding (10).
108
109 The accurate assessment of ghrelin in plasma has been proved to be challenging. Initial 
110 studies investigating plasma ghrelin levels in human samples reported ghrelin plus DAG levels 
111 (usually referred to as total ghrelin), as the early available commercial immunoassays did not 
112 discriminate the acylated and desacylated forms of the peptide (13, 14). Only the subsequent 
113 development of immunoassays to specifically assess ghrelin or DAG allowed the independent 
114 quantification of these two peptides in plasma. The assessment of ghrelin is also affected by the 
115 instability of the octanoyl modification since the ester bond is highly susceptible to be 
116 spontaneously hydrolysed at physiological pH and also a substrate of plasma esterases that rapidly 
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117 des-acylate ghrelin (15). Only recently the methods of collection, handling and storage of plasma 
118 samples have been standardized for the correct assessment of ghrelin (14).
119
120 Different studies show an association between ghrelin and obesity. In adults, ghrelin levels 
121 decrease in patients with obesity and negatively correlate with body mass index (BMI) (16, 17). 
122 Ghrelin levels also decrease in children and adolescents with obesity (18) and negatively correlate 
123 with BMI (13, 19, 20, 21). Notably, only few studies have independently assessed ghrelin and DAG 
124 levels in children with obesity, and observations have been inconsistent (13, 19, 22, 23, 24). Many 
125 studies found that ghrelin levels negatively correlates with circulating insulin and insulin resistance 
126 in adults and children (13, 24, 25, 26, 27). In contrast, studies looking for associations between 
127 plasma ghrelin and circulating lipids have reported inconsistent results (24, 28, 29, 30, 31). Thus, it 
128 seems evident that more clinical studies performing careful biochemical analyses in diverse human 
129 populations are still necessary for a better understanding of the implications of the ghrelin system 
130 in human beings. Regarding LEAP2, a recent study reports that LEAP2 levels are higher in patients 
131 with morbid obesity and positively correlate with BMI and plasma glucose (32). To our knowledge, 
132 plasma LEAP2 levels have not been investigated in children.
133
134 As a manoeuvre to assess the status of the ghrelin system, plasma levels of ghrelin and 
135 DAG have been combined to generate several indices. The sum of ghrelin plus DAG could be 
136 considered indicative of the total ghrelin production. Since DAG appears to be a functional 
137 inhibitor of ghrelin (7, 15), the ghrelin/DAG ratio has been used to estimate the effective ghrelin 
138 tone. Some studies show that the ghrelin/DAG ratio is a useful biomarker of excessive weight gain, 
139 even prior to the start of hyperphagia in subjects with Prader-Willi syndrome (13). Increased 
140 ghrelin/DAG ratio is also linked to obesity and diabetes (13, 19, 33, 34, 35). Since LEAP2 blocks 
141 ghrelin actions, we hypothesized that the ghrelin/LEAP2 ratio could provide another estimation of 
142 the effective ghrelin tone. The aim of our study was to evaluate the plasma levels of ghrelin, DAG 
143 and LEAP2 in children with overweight or obesity and their association with different 
144 anthropometric and metabolic variables, investigating also a potential sexual dimorphism.
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147 Study design. The study was approved by the Institutional Committee for the Revision of 
148 Research Protocols (CIRPI) of the Institute of Development and Paediatric Research (IDIP), La Plata 
149 Children´s Hospital, and conducted according to the Declaration of Helsinki guidelines and 
150 Argentinian legal provisions governing clinical research on humans. Written informed consent and 
151 assent were obtained from all participants, as appropriate. Participants were recruited from the 
152 obesity program of the Nutrition Service at Sor María Ludovica Children´s Hospital and from Elina 
153 de la Serna Children's Hospital (La Plata, Buenos Aires, Argentina), from April to December 2018.
154
155 Study participants. This cross-sectional cohort included 82 children, 3–12 years-old, 
156 without chronic medical illness, a personal history of diabetes, history of medical condition, or 
157 medication related to obesity or diabetes risk status. Children were born with gestational age>37 
158 weeks and birth weight>2500g. Birth weight and gestational age were obtained from hospital 
159 records. All participants underwent a baseline evaluation, including a complete medical and family 
160 history and physical examination, including Tanner staging by a paediatrician. The study included 
161 only children at pre- or early-pubertal stages (Tanner stage I, II or III), and females who had not 
162 reached the menarche. Weight and height measurements were performed by nutrition staff. 
163 Weight was measured with the participants barefoot and wearing minimal clothing, on a 
164 mechanical scale (Co. AR. Me. Series E9637, Argentina) with a resolution of 10 g and expressed as 
165 Z-score and gender based on World Health Organisation (WHO) references according to the age 
166 (WAZ) (36). Height was measured with a Harpenden-type wall-mounted stadiometer (Holtain Ltd., 
167 United Kingdom) with a resolution of 1 mm and expressed as Z-score and gender based on WHO 
168 references according to the age (HAZ) (36). BMI was calculated by dividing weight by height 
169 squared (kg/m2) and expressed as Z-score and gender based on WHO references according to the 
170 age (BAZ)(36). As described by the WHO, children with a BAZ between -2 and +1 were considered 
171 normoweight (NW), above +1 BAZ were considered patients with overweight (OW), and above +2 
172 BAZ were considered patients with obesity (OB) (36). Children with a BAZ lower than -2 were 
173 considered wasted, and were not included in this study.
174
175 Blood samples. The participants were asked not to eat after 09:00 PM the night before the 
176 session. Between 09:00 and 11:00 AM, an overnight fasting blood sample was drawn from each 
177 child and collected on EDTA (1 mg/mL final) to measure plasma levels of glucose, insulin, total 
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178 cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
179 (LDL-C), very low density lipoprotein cholesterol (VLDL-C) and triacylglycerols (TG) levels. For 
180 ghrelin, DAG and LEAP2 determinations, blood samples were collected on EDTA (1 mg/mL final) 
181 and p-hydroxy-mercuribenzoic acid (0.4 mM final) and, then, plasmas were immediately acidified 
182 with HCl (0.1 N final) to preserve acylation (14). All samples were stored frozen at -80°C until 
183 analysis.
184
185 Laboratory analyses. Glucose, TC, TG, LDL-C, VLDL-C and HDL-C levels were measured 
186 using standard enzymatic procedures in a TARGA BT3000 PLUS analyser (Biotecnica Instruments, 
187 Italy). Insulin levels were assessed by chemiluminescence (Access Beckman Coulter, Switzerland). 
188 Insulin resistance was estimated by the homeostasis model assessment for insulin resistance 
189 (HOMA index) (37). Ghrelin and DAG levels were assessed using specific enzyme immunoassays 
190 (A05306 and A05319, respectively, Bertin Bioreagent, Bertin Technologies, France). Assays were 
191 performed according to manufacturer’s instructions. Briefly, 100 µl of standards, quality controls 
192 and samples (diluted 1:2 or 1:5 in buffer for ghrelin or DAG determinations, respectively) were 
193 added to the plate as well as 100 µl of the tracer antibody and incubated overnight at 4°C. 
194 Following 3 washes, Ellman’s reagent was added. After 60 min, the absorbance was measured at 
195 405 nm using a Packard SpectraCount BS10000 absorbance microplate reader (USA). LEAP2 levels 
196 were assessed using a specific enzyme immunoassay for human and mouse LEAP2 detection (EK-
197 075-40, Phoenix Pharmaceutical, USA) according to manufacturer’s instructions. This assay 
198 demonstrated linearity of dilution and parallelism, and detected lower levels of LEAP2 in plasma 
199 samples from calorie restricted mice (38). This LEAP2 ELISA assay kit has been recently validated in 
200 human samples (32).  Briefly, 25 µl of standards, quality controls and samples (diluted 1:25 in 
201 buffer) were incubated in the plate at room temperature with 50 µl of antibody. After 2 h, 25 µl of 
202 biotinylated LEAP2 were added and incubated overnight al 4°C. Following several washes, 
203 horseradish peroxidase was added and incubated for 1 h. Following 3 washes, 3,3′,5,5′-
204 Tetramethylbenzidine was added and incubated for 1 h. Finally, the reaction was stopped with HCl 
205 and absorbance was measured at 405 nm as described above. Ghrelin, DAG and LEAP2 levels were 
206 calculated from the corresponding calibration curves using logarithmic fitting in Graphpad Prism 5 
207 (USA). Ghrelin+DAG levels were computed on a molar basis by adding ghrelin and DAG 
208 concentrations. Ghrelin/DAG ratio was computed on a molar basis as ghrelin concentration 
209 divided by DAG concentration. Ghrelin/LEAP2 ratio was computed on a molar basis as ghrelin 
210 concentration divided by LEAP2 concentration.
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212 Statistics and data analyses. Statistical analyses were performed using the R software 
213 version 3.5.1. The Shapiro–Wilk test was applied to test whether variables showed a normal 
214 distribution. Variables normally distributed were summarized as mean ± standard deviation (sd), 
215 and nonparametric data were presented as median (interquartile range, IQR). Since some 
216 variables were positively skewed, they were square root transformed (DAG, ghrelin and 
217 Ghrelin+DAG) or log transformed (ghrelin/leap and ghrelin/DAG ratios, LEAP, insulin and HOMA 
218 index) for all subsequent analyses and expressed as mean (95% confidence interval) or geometric 
219 mean (95% confidence interval), respectively. Linear correlations between ghrelin levels and other 
220 variables was assessed using nonparametric (Spearman's) or parametric (Pearson's) correlations 
221 coefficients as appropriate. Comparisons between children with NW and children with OW/OB 
222 were conducted with T-test or Mann-Whitney for quantitative data and chi-square for categorical 
223 data. Differences between children with NW or OW/OB and gender were analysed with the use of 
224 2-way analysis of variance (ANOVA) using BAZ and gender as independent variables. The 
225 interaction term gender*BAZ was included in the ANOVA model and if it was considered not 
226 significant, the ANOVA was run again only with the main effects. Distribution of residuals was 
227 checked using the Shapiro-Wilk test and normal quantile plots. The statistical tests were two 
228 tailed, and the significance level was set at 5%. In order to study interdependencies among ghrelin, 
229 DAG, LEAP2 and variables that showed significant correlation with any other variable (BAZ, insulin, 
230 TG, VLDL-C, LDL-C and HDL-C), a hierarchical clustering was performed. This data set was 
231 normalized with mean=0 and sd=1, and data from children with NW and children with OW/OB 
232 were processed separately to construct their corresponding ordered heatmaps with dendrograms 
233 for participants and variables. The dendrograms were computed by agglomerative hierarchical 
234 clustering, using Euclidean distance metrics and group average as the similarity criterion. This 
235 analysis was performed using Orange software (39).
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238 Characteristics of study subjects. Among the 82 subjects, 36 (44%) and 46 (66%) children 
239 met BAZ criteria for NW or OW/OB, respectively. The OW/OB group included 18 children with OW 
240 and 28 children with OB. Among children with OB, 21 children had a BAZ between +2 and +4, and 
241 7 children had a BAZ higher than +4. The study included 42 (51%) females and 40 (49%) males. 
242 Table 1 shows some characteristics of the participant children. The age and birth weight were 
243 similar between groups, while WAZ and BAZ were higher in children with OW/OB, as compared to 
244 children with NW, as expected. Also, insulin levels and HOMA index were higher and HDL-C was 
245 lower in children with OW/OB, as compared to children with NW. The differences in HAZ between 
246 both groups, although statistically significant, are between the normal ranges. No changes were 
247 observed in other variables.
248
249 Plasma levels of ghrelin, DAG and LEAP2. Table 2 shows plasma levels of ghrelin, DAG and 
250 LEAP2 as well as indices based on these variables for children with NW or OW/OB, in all subjects 
251 and in male and female children separately. Ghrelin levels were similar between groups, while 
252 levels of DAG, ghrelin+DAG and LEAP2 were lower in children with OW/OB, as compared to 
253 children with NW, independently of the gender. Ghrelin/DAG ratio was higher in children with 
254 OW/OB, as compared to children with NW, independently of the gender. Ghrelin/LEAP2 ratio did 
255 not differ between groups. As the interaction term gender*BAZ was not significant in any 
256 comparison, it was excluded from the ANOVA. 
257
258 Correlation analyses. First, variables shown in Table 1 were subjected to correlation 
259 analyses with variables shown in Table 2. Results of correlation analyses are shown in Table 3. 
260 When all subjects were analysed together, ghrelin levels did not correlate with any assessed 
261 variable. In contrast, DAG, LEAP2 and ghrelin+DAG levels as well as the ratio of ghrelin/DAG 
262 significantly correlated with different variables. In particular, DAG levels negatively correlated with 
263 age, BAZ, glycaemia (r=-0.24, p=0.0307), insulin levels and HOMA index. Ghrelin+DAG levels 
264 positively correlated with age, BAZ, insulin levels and HOMA index, but did not correlate with 
265 glycaemia. LEAP2 levels negatively correlated with BAZ and birth weight (r=-0.27, p=0.0147). 
266 Ghrelin/DAG ratio positively correlated with age, BAZ, insulin levels and HOMA index, while 
267 ghrelin/LEAP2 ratio did not correlate with any assessed variable. For the lipid panel, no significant 
268 correlations were found with the exception of LEAP2 levels that negatively correlated only with 
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269 LDL-C levels. No significant correlations were found between ghrelin, DAG, LEAP2 or their indices 
270 and HAZ in any case.
271
272 Next, the same correlation analyses described above were separately conducted in 
273 children with either NW or OW/OB (Table 3). Ghrelin levels did not correlate with any assessed 
274 variable in none of the groups. DAG levels negatively correlated with age, insulin levels and HOMA 
275 index in both groups of children, and the correlations were stronger in children with OW/OB vs 
276 NW. DAG levels negatively correlated with glycaemia only in children with NW (r=-0.39, p=0.0199) 
277 while it negatively correlated with BAZ and positively correlated with HDL only in children with 
278 OW/OB. Ghrelin+DAG levels negatively correlated with age in both groups of children. 
279 Ghrelin+DAG levels negatively correlated with BAZ, insulin levels and HOMA index and positively 
280 correlated with HDL levels only in children with OW/OB. LEAP2 levels negatively correlated with 
281 BAZ only in children with NW, while it negatively correlated with birth weight (r=-0.37, p=0.0122) 
282 only in children with OW/OB. Ghrelin/DAG ratio positively correlated with age in both groups of 
283 children and with insulin levels and HOMA index only in children with OW/OB. The ghrelin/LEAP2 
284 ratio did not correlate with any assessed variable in any group. For the lipid panel, no significant 
285 correlations were found with the exception of LEAP2 levels that negatively correlated with LDL-C 
286 levels only in children with OW/OB.
287
288 Finally, correlation analyses of the same variables described above were separately 
289 conducted in male and female children (Table 4). Ghrelin levels did not correlate with any assessed 
290 variable in male or female children. DAG and ghrelin+DAG levels negatively correlated with age, 
291 BAZ, insulin levels and HOMA index in male and female children. Strikingly, DAG levels positively 
292 correlated with LDL levels only in male children and negatively correlated with TG, LDL-C and 
293 VLDL-C levels only in female children. Ghrelin+DAG levels negatively correlated with TG and VLDL-
294 C levels only in female children. LEAP2 levels negatively correlated with BAZ only in male children, 
295 while it negatively correlated with birth weight (r=-0.38, p=0.0162) only in female children. 
296 Ghrelin/DAG ratio positively correlated with age, insulin levels and HOMA index in both male and 
297 female children. In male children, ghrelin/DAG ratio negatively correlated with LDL-C levels and 
298 positively correlated with BAZ, while in female children it negatively correlated with TG, LDL-C and 
299 VLDL-C levels. The ghrelin/LEAP2 ratio did not correlate with any assessed variable in any group.
300
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301 Study of interdependencies by agglomerative hierarchical clustering. Hierarchical clustering 
302 showed that metabolic and anthropometric variables cluster differently in children with NW or 
303 with OW/OB (Fig. 1). In NW, ghrelin and LEAP2 clustered together as well as LDL and DAG. In 
304 children with OW/OB, ghrelin and LEAP2 are no longer clustered together, while DAG clusters with 
305 HDL.
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308 Here, we assessed plasma levels of ghrelin, DAG and LEAP2 in children with NW or with 
309 OW/OB and investigated their association with anthropometric and metabolic variables. To our 
310 knowledge, this is the first clinical study that reports circulating levels of LEAP2, a recently 
311 discovered GHSR ligand, in a paediatric population. In addition, we explored the association of 
312 ghrelin/DAG and ghrelin/LEAP2 ratios with different anthropometric and metabolic variables. 
313
314 The paediatric population under study included 46 children that met BAZ criteria for 
315 OW/OB. We found high plasma insulin levels and HOMA index in children with OW/OB, indicating 
316 insulin resistance. Also, we found that HDL-C was 8% lower, while total cholesterol, LDL-C and 
317 VLDL-C remained unchanged, showing that alterations in glucose homeostasis appear early in 
318 children with OW/OB and they are more evident than changes in the lipid profile. These outcomes 
319 agree with the notion that decreased insulin sensitivity and dyslipidaemia can occur in children 
320 and adolescents as a result of obesity (40).
321
322 Also, we found lower DAG levels, a slight (8%) but not significant reduction of ghrelin 
323 levels, and a consequent reduction of the ghrelin/DAG ratio and the ghrelin+DAG levels in children 
324 with OW/OB. To the best of our knowledge, ghrelin and/or DAG levels in children were 
325 independently assessed only in six studies (13, 19, 22, 23, 24, 35). A reduction of DAG levels has 
326 been consistently reported in adults (33, 41), adolescents (22, 23) and pre-pubertal children (19, 
327 23) with obesity. In contrast, studies assessing ghrelin levels in individuals with obesity reported 
328 inconsistent results. Some studies found a significant decrease (33-45 %) of ghrelin levels in adults 
329 (32, 41, 42) and pre-pubertal (13, 19, 24) and pubertal children (19) with obesity. In contrast, and 
330 in agreement with our results, other studies reported a slight (16%) or no reduction of ghrelin 
331 levels in adults (31, 33), children and adolescents (22, 23, 35) with obesity. The reasons for the 
332 divergent findings are unknown, but may be related to methodological differences in plasma 
333 sampling and storage, which are critical for a hormone inherently unstable such as ghrelin. 
334 Importantly, we confirmed that ghrelin+DAG levels are decreased in individuals with OW/OB, as 
335 reported in most studies (16, 17, 19, 29). Since ghrelin is converted to DAG in plasma, the 
336 simultaneous assessment of ghrelin and DAG appears as a better estimation of the status of the 
337 ghrelin system. Interestingly, we found that plasma levels of ghrelin and DAG showed no gender 
338 differences in any condition, in line with previous studies in children (19, 24) and adults (16, 17). 
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339 To our knowledge, plasma ghrelin+DAG levels show sexual dimorphism only in adolescents, when 
340 levels are higher in females than in males (27).
341
342 We show here, for the first time that lower LEAP2 levels are detected in children with 
343 OW/OB. No gender differences were found in plasma LEAP2 levels. Such observation suggests that 
344 obesity affects not only the predominance of ghrelin forms but also other GHSR ligands. LEAP2 
345 blocks ghrelin effects (11, 12); thus, a reduction of LEAP2 levels in children with obesity would 
346 facilitate the orexigenic and diabetogenic effects of ghrelin. Interestingly, the levels of LEAP2 we 
347 detected in children with NW are similar to the levels recently reported in adults with NW (32). In 
348 contrast, this study found that plasma LEAP2 levels were similar between subjects with NW and 
349 subjects with obesity that had a BMI lower than 40 kg/m2 (32). A significant elevation of plasma 
350 LEAP2 levels was only detected in patients with BMI higher than 40 kg/m2 (32). Thus, plasma 
351 LEAP2 levels seem to be affected only under severe obesity conditions in adults. The reasons for 
352 the divergent results between adults and children are uncertain. 
353
354 DAG and ghrelin+DAG negatively correlated with BAZ only in children with OW/OB, in a 
355 gender-independent manner. LEAP2 levels also correlated with BAZ, and such correlation was 
356 significant only in male children and in children with NW. These observations suggest that the 
357 mechanisms that link the levels of DAG and LEAP2 to body weight are altered in children with 
358 OW/OB. Hierarchical clustering analysis also indicated that the interdependence of DAG and 
359 LEAP2 with other variables, including BAZ, was different in children with OW/OB. Notably, DAG 
360 levels and levels of ghrelin+DAG negatively correlated with age, in a gender- and BAZ-independent 
361 manner. Similar results were previously reported by other studies in diverse populations, many of 
362 which include adolescents (13, 19, 21, 43, 44). Indeed, levels of ghrelin+DAG negatively correlated 
363 with the pubertal stage (19, 21). Overall, clinical data indicate that the ghrelin system plays a more 
364 relevant role at younger ages, when its regulatory effects on GH secretion could be more 
365 important. In line with this notion, studies in mice show that endogenous ghrelin modulates GH 
366 secretory episodes primarily during the rapid phase of growth (45). Still, it is worth mentioning 
367 that we found that levels of ghrelin, DAG or LEAP2 did not correlate with height (expressed as 
368 HAZ) in children, in agreement with other authors (21), suggesting that the plasma levels of these 
369 peptides are not directly linked to growth. The extent to which alterations of the ghrelin system 
370 affect the growth of children with OW/OB remains uncertain.
371
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372 DAG levels negatively correlated with insulin and HOMA index, in a BAZ- and gender-
373 independent manner. Levels of ghrelin+DAG also negatively correlated with insulin and HOMA 
374 index but these correlations were significant only in children with OW/OB, in a gender-
375 independent manner. Levels of ghrelin did not correlate with insulin and HOMA index, similarly as 
376 previously reported (33). Current observations are in line with the idea of a crosstalk between DAG 
377 and glycaemic control, which appears to be independent of obesity, and also highlight the 
378 beneficial role of DAG in glycaemic control that, in turn, may be dependent or independent of the 
379 inhibitory role of DAG on ghrelin effects (6, 7, 8). Regarding the lipid profile, we mainly found weak 
380 associations. LEAP2 levels negatively correlated with LDL-C, and such correlation only showed 
381 statistical significance in children with OW/OB in a gender-independent manner. Thus, a potential 
382 role of LEAP2 in obesity-related dyslipidaemia should be further studied.  DAG levels as well as 
383 ghrelin+DAG negatively correlated with TG, VLDL-C and LDL-C exclusively in females. DAG levels 
384 negatively correlated with LDL-C in females, and positively correlated with LDL-C in males. 
385 Previous studies also reported similar weak correlations between circulating lipids and ghrelin, 
386 although no gender differences were reported (24, 28, 29, 30, 31). The weakness of the detected 
387 associations limits the ability to provide any certain conclusion in this regard. 
388
389 Here, we compared ghrelin/LEAP2 and ghrelin/DAG ratios to determine their degree of 
390 association with different variables. The ghrelin/DAG ratio has been widely linked to obesity and 
391 insulin resistance (13, 19, 33, 34, 35). In agreement with our results, several authors reported that 
392 this ratio is increased in patients with obesity, either adults (33), children or adolescents (13, 35). 
393 The increase of the ghrelin/DAG ratio occurs as a consequence of the reduction of DAG levels, an 
394 unbalance that would facilitate the orexigenic and diabetogenic effects of ghrelin in children with 
395 OW/OB, as previously discussed for LEAP2. As expected, the ghrelin/DAG ratio positively 
396 correlated with variables that negatively correlate with DAG. In particular, ghrelin/DAG ratio 
397 positively correlated with age (in a gender- and BAZ-independent manner), with BAZ (exclusively in 
398 male children, in a BAZ-independent manner) and with insulin levels and HOMA index (in the 
399 whole population, and in children with OW/OB, in a gender-independent manner). In adults, the 
400 observation that ghrelin/DAG ratio correlates with insulin and HOMA index only in patients with 
401 OW/OB has been proposed as an indication that the ghrelin/DAG ratio contributes to modulate 
402 insulin action in obese conditions (33). Since LEAP2 blocks constitutive and ghrelin-evoked GHSR 
403 signalling (11), we hypothesized that the ghrelin/LEAP2 ratio could be useful to estimate ghrelin 
404 tone in children with obesity. Notably, the above referred study assessing LEAP2 in adults found 
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405 lower plasma ghrelin and higher plasma LEAP2 levels in patients with severe obesity and, as a 
406 consequence, the ghrelin/LEAP2 ratio was decreased in these patients (32). In contrast, we found 
407 that the ghrelin/LEAP2 ratio remained unaffected in children with OW/OB, in a gender-
408 independent manner, and it showed no correlation with any of the metabolic or anthropometric 
409 variables studied. Thus, the ghrelin/LEAP2 ratio did not provide any additional information in 
410 children. 
411
412 In summary, we used specific commercial enzyme immunoassays to assess ghrelin, DAG 
413 and LEAP2 in plasma samples, which were carefully collected and stored, from fasted children with 
414 NW or OW/OB. We found that ghrelin levels did not differ between both groups, while DAG and 
415 LEAP2 decreased in children with OW/OB. Thus, we conclude that ghrelin tone is increased in 
416 childhood obesity, due to a decrease of plasma levels of DAG and LEAP2. Also, we found that DAG 
417 is associated to insulin resistance, particularly in children with OW/OB. Notably, no highly relevant 
418 gender differences were found.
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628 Fig. 1: Agglomerative hierarchical clustering and heatmap diagram of ghrelin, DAG, LEAP2, BAZ, 
629 insulin, TG, VLDL, LDL and HDL in NW children (panel A) and in children with OW/OB (panel B). The 
630 metabolic and anthropometric variables (top row) and participants (left) are clustered 
631 hierarchically. Each column represents a variable and each row represents a participant in the 
632 study. Intensity of yellow or red colour represents low or high values, respectively, of the 
633 normalized data.
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Table 1: Baseline characteristics of patients
 NW OW/OB p- value
Age (yr) 7.56 ± 2,41 8.12  ±  2,54 0.269
Birthweight (g) 3491.4  ±  352.1 3474.2  ±  524.2 0.860
WAZ -0.42  ± 0.74 2.61  ± 1.51 <0.0001
HAZ -0.60  ±  1.09 0.51  ±  1.10 <0.0001
BAZ 0.33 (-0.35; 0.60) 2.85 (1.92; 3.51) <0.0001
Insulin (IU mL-1) 2.95 (2.38; 3.64) 7.60 (5.74; 10.07) <0.0001
Glucose (mmol L-1) 4.45  ±  0.43 4.52  ±  0.49 0.508
HOMA index 0.58 (0.46; 0.72) 1.52 (1.14; 2.03) <0.0001
Total cholesterol (mg dL-1) 1.57  ±  0.22 1.56  ± 0.37 0.898
HDL-C (mg dL-1) 0.48  ±  0.09 0.44  ±  0.09 0.037
LDL-C (mg dL-1) 0.91  ±  0.24 0.93  ±  0.33 0.817
VLDL-C (mg dL-1) 0.15 (0.12; 0.19) 0.16 (0.12; 0.24) 0.121
TG (mg dL-1) 0.74 (0.58; 0.93) 0.80 (0.61; 1.17) 0.081
Abbreviations: WAZ: weight z-score; HAZ: height z-score; BAZ: BMI z-score; HOMA: homeostatic 
model assessment; HDL-C: high-density lipoprotein cholesterol; LDL-C: low density lipoprotein 
cholesterol; VLDL-C: very low density lipoprotein cholesterol; TG: triglycerides. Data are presented 
as mean±sd for age, glucose, total cholesterol, HDL-C and LDL-C. Insulin and HOMA index are 
presented as geometric mean (95% confidence interval). BAZ, VLDL-C and TG are presented as 
median (IQR). Bold values are statistically significant (p<0.05).
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Table 2. Plasma levels of ghrelin, DAG and LEAP2 and their indices in all the subjects and in male and female children
NW OW/OB ANOVA p-value
 
All Male Female All Male Female gender BAZ
Ghrelin 
(fmol mL-1)
7.55 (5.75; 9.61) 7.17 (5.00; 9.74) 8.10 (4.88; 12.14) 6.97 (5.72; 8.35) 7.58 (5.37; 10.16) 6.49 (5.04; 8.12) 0.8340 0.6070
DAG 
(fmol mL-1)
42.10 (34.88; 50.00) 42.74 (33.80; 52.71) 41.22 (28.52; 56.25) 23.95 (18.97; 29.50) 22.80 (16.76; 29.77) 24.93 (17.15; 34.17) 0.8550 0.0001
Ghrelin+DAG 
(fmol mL-1)
51.09 (43.63; 59.13) 51.00 (41.59; 61.38) 51.21 (38.18; 66.14) 32.33 (27.17; 37.94) 31.82 (25.59; 38.73) 32.76 (24.62; 42.06) 0.8850 0.0001
LEAP2 
(pmol mL-1)
2.98 (2.62; 3.40) 3.06 (2.57; 3.64) 2.88 (2.31; 3.59) 2.32 (2.01; 2.68) 2.43 (2.10; 2.81) 2.24 (1.75; 2.86) 0.472 0.0135
Ghrelin/DAG 
ratio
0.17 (0.12; 0.23) 0.16 (0.11; 0.23) 0.18 (0.10; 0.33) 0.30 (0.22; 0.43) 0.33 (0.20; 0.55) 0.29 (0.17; 0.47) 0.929 0.0151
Ghrelin/LEAP2 
ratio (x10-3)
2.21 (1.70; 2.87) 2.10 (1.51; 2.92) 2.37 (1.48; 3.80) 2.68 (2.07; 3.47) 2.76 (1.91; 3.97) 2.62 (1.78; 3.86) 0.8960 0.2980
Abbreviations: DAG: des-acyl ghrelin; LEAP2: liver antimicrobial peptide 2. Data are presented as mean (95% confidence interval) for ghrelin, DAG 
and ghrelin+DAG. Ghrelin/DAG ratio, LEAP2 and Ghrelin/LEAP2 ratio are presented as geometric mean (95% confidence interval). As the 
interaction term gender*BAZ was not significant in any model, it was excluded from de ANOVA. ANOVA p-values in bold are statistically 
significant (p<0.05).
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Table 3. Correlations between DAG and LEAP2 and calculated indices with age, BAZ, insulin, 
HOMA index and LDL-C in all the subjects and in children with NW or OW/OB 
Group Ghrelin DAG Ghrelin+DAG LEAP2 Ghrelin/DAG Ghrelin/LEAP2
Age All -0.01 -0.58 -0.58 0.04 0.40 -0.04
NW 0.06 -0.51 -0.50 -0.11 0.33 0.12
OW/OB -0.07 -0.66 -0.66 0.14 0.47 -0.16
BAZ All -0.1 -0.48 -0.50 -0.35 0.27 0.05
NW -0.29 -0.14 -0.26 -0.40 -0.15 -0.10
OW/OB -0.14 -0.32 -0.33 -0.07 0.19 -0.13
Insulin All 0.08 -0.59 -0.52 0.03 0.48 0.07
NW 0.00 -0.34 -0.24 0.10 0.19 -0.03
OW/OB 0.16 -0.59 -0.50 0.25 0.56 0.01
HOMA index All 0.1 -0.59 -0.51 0.04 0.49 0.07
NW 0.00 -0.35 -0.25 0.08 0.20 -0.05
OW/OB 0.18 -0.60 -0.50 0.27 0.57 0.01
LDL-C All -0.04 0.01 0.00 -0.26 -0.02 0.15
NW -0.10 0.18 0.13 -0.20 -0.20 0.16
OW/OB 0.02 -0.08 -0.08 -0.31 0.07 0.19
HDL-C All -0.02 0.15 0.13 -0.11 0.16 0.06
NW -0.09 -0.24 -0.30 -0.10 -0.11 -0.02
OW/OB -0.11 0.34 0.31 -0.21 0.27 0.14
Abbreviations: DAG: des-acyl ghrelin; LEAP2: liver antimicrobial peptide 2, BAZ: BMI z-score; 
HOMA: homeostatic model assessment; LDL-C: low density lipoprotein cholesterol; HDL-C: high 
density lipoprotein cholesterol; NW: normoweight; OW/OB: overweight/obese. Bold values are 
statistically significant (p<0.05).
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Table 4. Correlations between DAG and LEAP2 and calculated indices with age, BAZ, insulin, 
HOMA index, VLDL-C, LDL-C and TG in all the subjects and in male and female children
Group Ghrelin DAG Ghrelin+DAG LEAP2 Ghrelin/DAG Ghrelin/LEAP2
Age All -0.01 -0.58 -0.58 0.04 0.40 -0.04
Male 0.00 -0.56 -0.61 0.01 0.31 -0.03
Female -0.05 -0.60 -0.57 0.07 0.46 -0.07
BAZ All -0.10 -0.48 -0.50 -0.35 0.27 0.05
Male -0.04 -0.56 -0.59 -0.45 0.31 0.15
Female -0.20 -0.38 -0.43 -0.25 0.23 -0.08
Insulin All 0.08 -0.59 -0.52 0.03 0.48 0.07
Male 0.06 -0.57 -0.55 0.02 0.38 0.05
Female 0.03 -0.60 -0.55 0.09 0.55 0.03
HOMA index All 0.10 -0.59 -0.51 0.04 0.49 0.07
Male 0.08 -0.59 -0.55 -0.02 0.40 0.06
Female 0.07 -0.58 -0.51 0.09 0.56 0.06
VLDL-C All -0.09 -0.21 -0.19 0.02 0.12 -0.08
Male -0.20 0.03 0.01 0.18 -0.18 -0.26
Female -0.03 -0.44 -0.41 -0.03 0.42 0.00
LDL-C All -0.04 0.01 0.00 -0.26 -0.02 0.15
Male -0.23 0.34 0.23 -0.22 -0.41 -0.09
Female 0.17 -0.32 -0.26 -0.28 0.39 0.30
HDL-C All -0.02 0.15 0.13 -0.11 0.16 0.06
Male 0.03 0.12 0.11 -0.13 0.07 0.10
Female -0.05 0.15 0.15 -0.10 0.22 -0.23
TG All -0.09 -0.17 -0.15 -0.05 0.08 -0.04
Male -0.21 0.02 0.00 0.12 0.19 -0.25
Female 0.03 -0.34 -0.33 0.13 0.33 0.07
Abbreviations: DAG: des-acyl ghrelin; LEAP2: liver antimicrobial peptide 2, BAZ: BMI z-score; 
HOMA: homeostatic model assessment; VLDL-C: very low density lipoprotein cholesterol; LDL-C: 
low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; TG: triglycerides. 
Bold values are statistically significant (p<0.05).
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Fig. 1: Agglomerative hierarchical clustering and heatmap diagram of ghrelin, DAG, LEAP2, BAZ, insulin, TG, 
VLDL, LDL and HDL in NW children (panel A) and in children with OW/OB (panel B). The metabolic and 
anthropometric variables (top row) and participants (left) are clustered hierarchically. Each column 
represents a variable and each row represents a participant in the study. Intensity of yellow or red colour 
represents low or high values, respectively, of the normalized data. 
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